Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abdullah Sakin

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Clinical Medicine Insights. Oncology|May 14, 2026
Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group StudySedat Yildirim, Ozlem Nuray Sever, Ezgi Turkoglu, et al.
Bosnian Journal of Basic Medical Sciences|April 23, 2022
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancerSelin Aktürk Esen, Yakup Ergun, Cihan Erol, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Breast Cancer Research and Treatment|August 9, 2024
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG studyİsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, et al.
BMC Cancer|November 22, 2025
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access programMehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyPınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyAhmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Journal of Chemotherapy (Florence, Italy)|May 17, 2022
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group studyTuğba Başoğlu, Abdullah Sakin, Cihan Erol, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Clinical Medicine Insights. Oncology|May 14, 2026
Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group StudySedat Yildirim, Ozlem Nuray Sever, Ezgi Turkoglu, et al.
Bosnian Journal of Basic Medical Sciences|April 23, 2022
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancerSelin Aktürk Esen, Yakup Ergun, Cihan Erol, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Breast Cancer Research and Treatment|August 9, 2024
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG studyİsmail Beypınar, Hacer Demir, Şendağ Yaslıkaya, et al.
BMC Cancer|November 22, 2025
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access programMehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyPınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyAhmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Journal of Chemotherapy (Florence, Italy)|May 17, 2022
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group studyTuğba Başoğlu, Abdullah Sakin, Cihan Erol, et al.
Pageof 11